COMBINATION THERAPY OF SMALL-CELL LUNG-CA NCER WITH TENIPOSIDE, IFOSFAMIDE AND CARBOPLATIN

Thirty six SLC patients have been treated with a combination therapy o f ifosfamide 2 g/m2, D1 and D2, carboplatin 300 Mg/m2 D1 and teniposid e 100 mg/m2 D1 to D3. All patients were younger than 70 years, 31 male s, five females, ten limited diseases, 26 extended diseases (without b rain metastasis) Perfomance status 0, 1 or 2, mean weight loss 3,7 kg. Thirty six patients were evaluable for response. We have noted three complete response and 28 partial response (objective response rate 86% ). The main toxicity of this combination therapy was myelosuppression (86% of grade 3 and 4). Twenty seven patients have relapsed, the media n relapse free survival time is 310 days. The median survival of the 3 6 patients is 340 days, one patient is alive more than 30 months after the diagnosis. The ifosfamide-carboplatin-teniposide combination is a n effective treatment in small cell lung cancer, its toxicity remains tolerable.